

**Conclusion** Preoperative imaging and histological result are key factors in the precise treatment plan of endometrial cancer, but depend greatly on the level of institution the tests are performed in.

**Disclosures** The authors have no conflict of interest.

**#363 REVERSED SEQUENCE OF PORTEC PROTOCOL IN THE TREATMENT OF HIGH-RISK ENDOMETRIAL CANCER: AN ALTERNATIVE IN THE CONTEXT OF LOW AND MIDDLE-INCOME COUNTRIES**

Alia Latrous\*, Nesrine Mejri, Haifa Rachdi, Mariem Saadi, Yosra Berrazaga, Lotfi Kochbati, Hamouda Boussem. *Abderrahman Mami Hospital, Ariana, Tunisia*

10.1136/ijgc-2023-ESGO.314

**Introduction/Background** The standard of care for high-risk endometrial cancer is based on the results of the PORTEC 3 trial, which recommends adjuvant chemoradiotherapy and chemotherapy after surgery. However, in some countries, such as Tunisia, accessing radiotherapy machines can be challenging with significant delays. We aimed to report the feasibility and safety of the reversed sequence strategy.

**Methodology** We retrospectively collected 40 cases of high-risk endometrial cancer treated with the reversed PORTEC sequence between 2021–2022. All included patients met the eligibility criteria of the PORTEC 3 trial. Patients received adjuvant chemotherapy (4 cycles of carboplatin/paclitaxel) followed by concurrent chemo-radiotherapy (Cisplatin S1-S4). We described the patient’s characteristics, treatment administration intervals, toxicity, and survival results.


**Results** Mean age was 60 years with obesity in 40% of patients and hypertension in 53%. ECOG PS was 0–1 in 74% of patients. Histological subtypes were endometrioid (65%), serous(17.5%), and clear cell (7.5%). High-grade tumors were seen in 61%, with 59% of nodal involvement and 50% of lymph-vascular invasion. All patients had surgery consisting of hysterectomy and bilateral salpingo-oophorectomy in 70% of cases and lymph node dissection in 75%. The median time between surgery and chemotherapy was 3months (2–6 months) and between chemotherapy and concurrent chemo-radiotherapy 3 months (1–8 months). Chemotherapy all grades toxicities were reported in 35% of cases as follows: 65%neuropathy (5% G3),8% of G3–4 neutropenia (4% febrile neutropenia), 15% anemia, 10% thrombocytopenia, 25% gastrointestinal toxicities. No grade 3–4 toxicities were reported during concurrent chemo-radiotherapy. 94% of patients completed all therapy sequences. After a median follow-up of 15 months, the recurrence rate was 15% (33% locoregional, 67% metastatic). the median time to relapse of 14 months. Overall survival at 2 years was 80%.

**Conclusion** Reversed PORTEC sequence may be a feasible, safe, and effective treatment alternative for high-risk endometrial cancer to overcome the challenges of delayed radiotherapy initiation.


**Disclosures** No conflicts of interest.




**Conflict of Interest Disclosure Statement**  
The European Society of Gynaecological Oncology requires their members to disclose their financial interests from all potential or actual conflicts regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced professional conduct.  
Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.  
NAME: MAMI RACHDI  
AFFILIATION: \_\_\_\_\_  
 I have no potential conflict of interest to report  
 I have the following potential conflict(s) of interest to report:  
**Type of affiliation / financial interest** Name of commercial company / details  
Receipt of grants/research supports: \_\_\_\_\_  
Receipt of honoraria or consultation fees: \_\_\_\_\_  
Participation in a company sponsored speaker's bureau: \_\_\_\_\_  
Stock shareholder: \_\_\_\_\_  
Spouse/partner: \_\_\_\_\_  
Other support (please specify): \_\_\_\_\_  
Signature: [Signature] Date: 15/05/2023




**Conflict of Interest Disclosure Statement**  
The European Society of Gynaecological Oncology requires their members to disclose their financial interests from all potential or actual conflicts regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced professional conduct.  
Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.  
NAME: MAMI RACHDI  
AFFILIATION: \_\_\_\_\_  
 I have no potential conflict of interest to report  
 I have the following potential conflict(s) of interest to report:  
**Type of affiliation / financial interest** Name of commercial company / details  
Receipt of grants/research supports: \_\_\_\_\_  
Receipt of honoraria or consultation fees: \_\_\_\_\_  
Participation in a company sponsored speaker's bureau: \_\_\_\_\_  
Stock shareholder: \_\_\_\_\_  
Spouse/partner: \_\_\_\_\_  
Other support (please specify): \_\_\_\_\_  
Signature: [Signature] Date: 15/05/23



**Conflict of Interest Disclosure Statement**  
The European Society of Gynaecological Oncology requires their members to disclose their financial interests from all potential or actual conflicts regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced professional conduct.  
Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.  
NAME: MAMI RACHDI  
AFFILIATION: \_\_\_\_\_  
 I have no potential conflict of interest to report  
 I have the following potential conflict(s) of interest to report:  
**Type of affiliation / financial interest** Name of commercial company / details  
Receipt of grants/research supports: \_\_\_\_\_  
Receipt of honoraria or consultation fees: \_\_\_\_\_  
Participation in a company sponsored speaker's bureau: \_\_\_\_\_  
Stock shareholder: \_\_\_\_\_  
Spouse/partner: \_\_\_\_\_  
Other support (please specify): \_\_\_\_\_  
Signature: [Signature] Date: 15/05/2023



**Conflict of Interest Disclosure Statement**  
The European Society of Gynaecological Oncology requires their members to disclose their financial interests from all potential or actual conflicts regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced professional conduct.  
Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.  
NAME: MAMI RACHDI  
AFFILIATION: \_\_\_\_\_  
 I have no potential conflict of interest to report  
 I have the following potential conflict(s) of interest to report:  
**Type of affiliation / financial interest** Name of commercial company / details  
Receipt of grants/research supports: \_\_\_\_\_  
Receipt of honoraria or consultation fees: \_\_\_\_\_  
Participation in a company sponsored speaker's bureau: \_\_\_\_\_  
Stock shareholder: \_\_\_\_\_  
Spouse/partner: \_\_\_\_\_  
Other support (please specify): \_\_\_\_\_  
Signature: [Signature] Date: 15/05/2023



**Conflict of Interest Disclosure Statement**  
The European Society of Gynaecological Oncology requires their members to disclose their financial interests from all potential or actual conflicts regarding any financial holdings, funding sources, or affiliations that might raise questions of bias or be perceived to have potentially influenced professional conduct.  
Please disclose any financial relationship from the past three years (dating from the month of submission) of any size.  
NAME: MAMI RACHDI  
AFFILIATION: \_\_\_\_\_  
 I have no potential conflict of interest to report  
 I have the following potential conflict(s) of interest to report:  
**Type of affiliation / financial interest** Name of commercial company / details  
Receipt of grants/research supports: \_\_\_\_\_  
Receipt of honoraria or consultation fees: \_\_\_\_\_  
Participation in a company sponsored speaker's bureau: \_\_\_\_\_  
Stock shareholder: \_\_\_\_\_  
Spouse/partner: \_\_\_\_\_  
Other support (please specify): \_\_\_\_\_  
Signature: [Signature] Date: 15/05/2023